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Abstract
Treatment of relapsed/resistant acute myeloid leukaemia (AML) remains a signifi-
cant area of unmet patient need, the outlook for most patients remaining extremely
poor. A promising approach is to augment the anti-tumour immune response in
these patients; most cancers do not activate immune effector cells because they
express immunosuppressive ligands. We have previously shown that CD200 (an
immunosuppressive ligand) is overexpressed in AML and confers an inferior overall
survival compared to CD200low/neg patients. Here we show that a fully human
anti-CD200 antibody (TTI-CD200) can block the interaction of CD200 with its
receptor and restore AML immune responses in vitro and in vivo.
Keywords: AML, CD200, immune check point, immunosuppression,
smouldering multiple myeloma.
Acute myeloid leukaemia (AML) is a highly heterogeneous
disease in which leukaemic stem cell (LSC) persistence is
considered to be the primary cause of relapse.1 Immune eva-
sion by LSC is an important determinant of relapse which is
mediated by expression of specific cell surface molecules with
immune modulatory function.2 Novel immune-directed ther-
apeutic approaches form a major focus of current and clini-
cal research.3 We have previously shown that CD200 is an
important immune checkpoint protein that is expressed
in c. 40% of AML patients and associates with poor progno-
sis.4 CD200 belongs to the immunoglobulin superfamily and
exerts immunosuppressive signalling through its receptor
CD200R, present on immune cells.5 We have previously
shown that CD200High AML patients exhibited reduced Nat-
ural Killer (NK) and T cell immune responses in comparison
to CD200Low patients, indicating that CD200 is a potential
immunotherapeutic target in this disease. Our results also
suggested that CD200 can be a contributing factor responsi-
ble for AML immune evasion and therapy relapse.6-9 With
this in mind, we used an anti-CD200-blocking antibody
(TTI-CD200) to assess whether CD200-mediated immuno-
suppression can be reversed in AML. TTI-CD200 is a fully
human antibody that neutralises human CD200 with
nanomolar potency, as determined through a cell-based assay
(Figure S1).
Initially, we determined the effective blocking concentra-
tion of TTI-CD200, using K562 cells over-expressing CD200
(K562-CD200+), by co-culturing them with normal human
NK cells (see Online Supplementary Materials and Methods).
As expected, diminished expression of the NK degranulation
marker CD107a was observed for K562-CD200+ compared to
K562-CD200- cells (Figure S2). Co-culturing K562-CD200+
in the presence of TTI-CD200 significantly recovered activity
of CD3-CD56dimCD16+ NK cells (equivalent to K562-CD200-
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cells), compared to isotype control (Figure S2A). Similarly,
we also observed an increase in Interferon gamma (IFN)-c
release from NK cells as measured by ELISPOT assay in the
presence of TTI-CD200, compared to isotype-treated cells
(Figure S2B). To test whether TTI-CD200 could have a func-
tional effect on immune cells ex vivo, AML patient blasts
with high or low levels of CD200 protein expression (as
described in 6) were co-cultured with their autologous lym-
phocytes in the presence of TTI-CD200 or isotype control. A
significant increase in CD107a expression was observed in
TTI-CD200 treated CD200High AML blasts in comparison
with isotype control-treated cells (Fig. 1A). As expected, no
increase in CD107a expression was observed in CD200Low
AML blasts treated with TTI-CD200 or isotype control. TTI-
CD200 treatment also led to significant increase in IFN-c
release in CD200High AML blasts in ELISPOT assay (Fig. 1B).
Our previous studies showed that CD200High AML patients
had a low frequency of IFN-c producing CD4+ Th1 cells
(CD19-CD3+CD4+CCR7-), which are central to adaptive
immune responses in AML.7 Therefore, we next determined
the impact of TTI-CD200-blocking on the frequency of these
cells in CD200High AML patients. As expected, an increase in
Fig 1. TTI-CD200 treatment improves immune responses of CD200High AML patient samples: (A) Bar graphs showing NK killer cell activity
measured as CD107 expression. Primary AML blasts from CD200High and CD200Low AML samples (previously determined by upper or lower
quartile of CD200 expression) with their autologous lymphocytes were treated with either TTI-CD200 or isotype control (5 lg/mL) for 6h in the
presence of Golgi stop. NK cell activity was measured as the surface expression of CD107a and represented as percentage of MFI relative to iso-
type control. (B) Bar graphs representing spots/wells as a measure of Interferon-c (IFN-c) production. Primary AML blasts from CD200High and
CD200Low AML samples (as above) were incubated with their autologous lymphocytes on ELISPOT plates, pre-coated with IFN-c capture anti-
body. IFN-c capture spots were counted manually under a light microscope and normalised with negative control wells without capture of IFN-c
antibody. (C) Bar graph showing frequency of active IFN- c-producing CD3+CD4+CCR7- effector memory T cells in CD200High AML samples.
AML samples with their autologous lymphocytes were treated with either TTI-CD200 or isotype control (5 l g/mL) for 6h, fixed and perme-
abilised, and stained for intracellular cytokines. The percentage of of IFN-c-producing cells was measured by flow cytometry based on cell surface
markers (details in supplementary methods). All datasets are represented as mean  1SD from three experiments. Statistical significance is
denoted by *P ≤ 005, analysed by unpaired ‘t’ test. [Colour figure can be viewed at wileyonlinelibrary.com]
Short Report
2 ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology and
John Wiley & Sons Ltd
frequency of IFN-c-producing CD4+ Th1 cells was observed
in the presence of TTI-CD200 (Fig. 1C). Taken together,
these data show that an ex vivo blockade of the CD200-
CD200R interaction with TTI-CD200 led to the recovery of a
significant proportion of immune activity.
To analyse the effect of TTI-CD200 in vivo, a robust
source of adoptive immune cells which could be co-engrafted
with AML blast cells into NOD-SCID IL2Rc(-/-) (NSG) mice
was required. Cytokine Induced Killer (CIK) cells are an
adoptive immune cellular therapy which had shown promis-
ing pre-clinical and clinical efficacy in AML, without causing
graft-versus-host-like disease which is normally observed with
adoptive transferred human T cells in immuno-deficient
mice.10 Also, CIK cells are readily expandable and effective at
killing tumour cells in a non-MHC-restricted manner. We
therefore selected CIK cells as our adoptive immune cells to
analyse the efficacy of TTI-CD200 in a xenograft model of
AML. Poh and Linn (2016) have also shown that surface
expression of immune checkpoint proteins (PD1, TIM3,
LAG3, CTLA-4 and CD200R) decreases their cytotoxicity
towards myeloid target cells, which can be reversed using
monoclonal antibodies (though CD200 was not tested). Ini-
tially, we determined the expression of CD200R on two
major cytotoxic populations of CIK cells (CD56+CD3+ and
Fig 2. TTI-CD200 sensitises AML cells towards CIK cell-mediated lysis ex vivo and in vivo. (A) Bar graphs represent percentage of cell lysis of
primary AML blast cells. Cells were pre-treated with either TTI-CD200 or isotype control (5 l g/mL) for 1h, followed by co-culture with CIK
cells for 5h with E:T of 10:1. Other E:T ratios are shown in supplemental Fig. S5. Percentage of cell lysis was calculated using flow cytometry and
shows the relative number of AML blasts recovered, following CIK cell co-culture in TT-CD200 and isotype-treated groups. Data are
mean  1SD from three experiments with * P ≤ 005 and ** P ≤ 001, analysed by Dunnett’s multiple comparison test. (B) Schematic plan for
in vivo experiments. NSG mice were injected with primary CD200High AML blasts. Mice were monitored for 8-10 weeks for AML engraftment by
bone marrow sampling and subsequently injected with CIK cells every seventh day, followed by treatment with TTI-CD200 or isotype (10mg/kg)
on the day, and every two days for eight times. (C) Data represent percentage of AML engraftment in NSG mice as analysed through flow cytom-
etry as the expression of hCD45+CD33+CD19-. Every point represents an individual mouse. Horisontal bar represents the mean with *P ≤ 005,
analysed by the Mann-Whitney test. [Colour figure can be viewed at wileyonlinelibrary.com]
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CD56-CD3+). CD200R expression was detectable in these
populations at day 10 of culture (Figure S3). To confirm that
CIK activity was inhibited by CD200, we co-cultured CIK
cells with K562-CD200+ cells and found that K562-CD200+
cells were less susceptible to CIK-mediated killing than K562-
CD200- cells (Figure S4A). Further, pre-treatment of K562-
CD200+ cells with TTI-CD200 increased CIK cell-mediated
cell lysis compared to isotype control (Figure S4B and S4C)
with the cytotoxicity of CIK cells maintained across different
effector to target (E:T) ratios (Figure S4D). Interestingly,
TTI-CD200 treatment increased surface expression of
CD107a on CIK cells, suggesting activation of the NK cell-
like phenotype.11 Together these data show that CD200 nega-
tively regulates the cytotoxic activity of CIK cells. We next
confirmed these findings using primary AML blasts ex vivo.
TTI-CD200 pretreatment increased CIK cell-mediated lysis of
CD200High AML blasts (Fig 2A). While the therapeutic bene-
fit of CIK cells has already been verified in AML patients,
CIK cells expressing chimeric antigen receptors (CAR) may
allow enhanced targeting of AML cells,11 although identifica-
tion of AML-specific antigens will be required. These find-
ings show that inhibition of CD200-CD200R signalling
significantly augments the cytotoxic potential of CIK cells
towards AML blasts; CD200 can therefore be considered a
good candidate for future CAR-CIK-based therapy in AML.
The above data suggest that TTI-CD200 can increase
immune activity of CIK cells ex vivo by relieving the CD200R
immunosuppression signal imparted by AML blasts. As a
proof of principle, to determine whether TTI-CD200 can
achieve similar results in vivo, we injected human CD200High
AML blast cells into NSG mice. Once AML engraftment was
achieved, CIK cells were subsequently injected weekly, fol-
lowed by administration of TTI-CD200 or Isotype control
every two days (Fig 2B). AML engraftment was assessed after
eight cycles of antibody treatment. We found a significant
decrease in percent engraftment of AML cells in the TTI-
CD200 treatment group compared to isotype control
(Fig 2C). Taken together, our findings illustrate for the first
time the use of CD200 monoclonal antibody in the context
of a xenotransplantation model of AML.
The efficacy of immune checkpoint inhibitors has been
well-established in recent years as they have gained therapeu-
tic approvals for solid tumours and in refractory non-Hodg-
kin Lymphoma.12 Monoclonal antibodies against immune
checkpoint proteins such as CTLA-4 (ipilimumab), PD-1
(nivolumab and pembrolizumab) and its ligand PD-L1 (dur-
valumab), TIM-3 (MBG453) are under active clinical investi-
gation in high risk as well as refractory/relapsed AML.3
However, a limited number of patients so far have benefited
from these agents as monotherapy.13 Various further studies
on combinatorial approaches have shown moderate but
promising clinical benefits to the patients but immune-
related adverse events (irAE) remain a potential concern for
this group of therapies.14 Therefore, identification of novel
immune checkpoint proteins used alone or in combination,
which have improved tolerability and clinical efficacy in the
refractory/relapse disease setting, is a major focus of current
AML research. Though the importance of CD200 in AML
prognosis and modulating immune response has already
been shown, little evidence of efficacy of an anti-CD200
monoclonal antibody have been documented in pre-clinical
models of AML to facilitate its clinical development. We
have shown that TTI-CD200 treatment not only enhanced
the function of autologous immune cells ex vivo but also sig-
nificantly improved efficacy of adoptive immune effector
CIK cells towards residual AML cells in vivo. Additional
studies suggest that CD200 may be a potential marker for
LSCs responsible for relapse in AML and that its targeting
can benefit patients with relapsed or refractory AML dis-
ease.15 Furthermore, significant correlation between CD200
and PDL1 in AML T cell immunosuppression has already
been shown by our group, suggesting that this combination
also holds potential for further evaluation in AML
immunotherapy.9 Therefore, we propose that blocking the
CD200-CD200R axis represents a potentially effective strategy
to treat AML and warrants further clinical investigation.
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Figure S1. TI-CD200 antibody inhibits CD200-mediated
suppression with nanomolar potency. The NK-sensitive tar-
get cell C1R expressing cell surface CD200 was incubated
with titrated TTI-CD200 antibody or isotype control for one
hour and then co-cultured with a human NK.
Figure S2. TTI-CD200 improves immune responses in
CD200High AML cells in vitro.
Figure S3. Expression of CD200 receptor on CIK cells.
Figure S4. TTI-CD200 treatment enhances CIK-mediated
lysis in AML cells in vitro.
Figure S5. CD200-blocking increases CIK-mediated cell
lysis in AML blasts.
References
1. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al.
Assessment of minimal residual disease in standard-risk AML. N Engl J
Med. 2016;374:422–33.
2. Austin R, Smyth MJ, Lane SW. Harnessing the immune system in acute
myeloid leukaemia. Crit Rev Oncol Hematol. 2016;103:62–77.
3. Hobo W, Hutten TJA, Schaap NPM, Dolstra H. Immune checkpoint
molecules in acute myeloid leukaemia: managing the double-edged sword.
Br J Haematol. 2018;181:38–53.
4. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK, et al. CD200 as
a prognostic factor in acute myeloid leukaemia. Leukemia. 2007;21:566–8.
5. Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane
protein interactions in the control of myeloid cells. Trends Immunol.
2002;23:285–90.
6. Coles SJ, Wang EC, Man S, Hills RK, Burnett AK, Tonks A, et al. CD200
expression suppresses natural killer cell function and directly inhibits
patient anti-tumor response in acute myeloid leukemia. Leukemia.
2011;25:792–9.
7. Coles SJ, Hills RK, Wang EC, Burnett AK, Man S, Darley RL, et al.
Expression of CD200 on AML blasts directly suppresses memory T-cell
function. Leukemia. 2012;26:2148–51.
8. Coles SJ, Hills RK, Wang EC, Burnett AK, Man S, Darley RL, et al. Increased
CD200 expression in acute myeloid leukemia is linked with an increased fre-
quency of FoxP3+ regulatory T cells. Leukemia. 2012;26:2146–8.
9. Coles SJ, Gilmour MN, Reid R, Knapper S, Burnett AK, Man S, et al. The
immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell
immunosuppression: identification of a new immunotherapeutic synapse.
Leukemia. 2015;29:1952–4.
10. Poh SL, Linn YC. Immune checkpoint inhibitors enhance cytotoxicity of
cytokine-induced killer cells against human myeloid leukaemic blasts. Can-
cer Immunol Immunother. 2016;65:525–36.
11. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S,
Spinelli O, et al. Chimeric antigen receptors against CD33/CD123 antigens
efficiently target primary acute myeloid leukemia cells in vivo. Leukemia.
2014;28:1596–605.
12. Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint
inhibitors: recent progress and potential biomarkers. Exp Mol Med.
2018;50:1–11.
13. Daver N, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J,
et al. Hypomethylating agents in combination with immune checkpoint
inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leu-
kemia. 2018;32:1094–105.
14. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE,
et al. Efficacy, safety, and biomarkers of response to azacitidine and nivo-
lumab in relapsed/refractory acute myeloid leukemia: a nonrandomized,
open-label. Phase II Study. Cancer Discov. 2019;9:370–83.
15. Ho JM, Dobson SM, Mcleod J, Voisin V, Murison A, Kennedy J, et al.
Isolation of CD34neg and CD34+ Leukemia Stem Cells from Acute Mye-
loid Leukemia Blasts Using CD200. Blood. 2018;132:2790.
Short Report
ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology and
John Wiley & Sons Ltd 5
